Dr. Reddy'S Active Pharmaceutical Ingredients

Dr. Reddy'S Active Pharmaceutical Ingredients company information, Employees & Contact Information

Dr. Reddy’s supplies high-quality APIs to leading formulation manufacturers across the world, enabling them to develop affordable medicines for patients worldwide. We are the preferred API partner to pharma companies across the US, Europe, Latin America, Japan, China, Korea and emerging markets. Our global establishment is rooted in deep technical strengths established over the last 38 years in the development and manufacture of complex APIs such as steroids, peptides, complex long-chain molecules, and highly potent APIs (HPAIs /oncology drugs). We have strong technical and cross-functional teams including R&D, Quality, Engineering & Analytical departments. Our dedicated R&D teams are committed to developing complex products to meet the evolving API needs in the GMP environment. Dr. Reddy's manufactures a wide range of pharmaceuticals in India and overseas. Our API manufacturing facilities are operated following cGMP (ICH Q7) and are regularly inspected by international regulatory authorities. We have eight commercial USFDA inspected production units, six in India and one in Mexico and the UK. Our APIs have regulatory filings available in major markets across the world. For more information, visit our website. For our community guidelines on LinkedIn: please visit: https://rb.gy/cddj9c

Company Details

Employees
96
Founded
-
Address
Hyderabad, Telangana, In
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Hyderabad, Telangana
Looking for a particular Dr. Reddy'S Active Pharmaceutical Ingredients employee's phone or email?

Dr. Reddy's Active Pharmaceutical Ingredients Questions

News

Unitaid, CHAI, and Wits RHI enter into a landmark agreement with Dr. Reddy’s to make HIV prevention tool lenacapavir affordable in LMICs - Clinton Health Access Initiative

Unitaid, CHAI, and Wits RHI enter into a landmark agreement with Dr. Reddy’s to make HIV prevention tool lenacapavir affordable in LMICs Clinton Health Access Initiative

Dr. Reddy’s Q1FY26 Financial Results - Business Wire

Dr. Reddy’s Q1FY26 Financial Results Business Wire

Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia - PR Newswire

Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia PR Newswire

Dr. Reddy’s Q4 & Full Year FY25 Financial Results - Business Wire

Dr. Reddy’s Q4 & Full Year FY25 Financial Results Business Wire

Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma - Yahoo Finance

Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma Yahoo Finance

Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business - NTB Kommunikasjon

Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business NTB Kommunikasjon

Alvotech and Dr. Reddy’s Announce FDA acceptance of - GlobeNewswire

Alvotech and Dr. Reddy’s Announce FDA acceptance of GlobeNewswire

Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year - Yahoo Finance

Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year Yahoo Finance

Dr. Reddy’s Q3 & 9MFY25 Financial Results - Business Wire

Dr. Reddy’s Q3 & 9MFY25 Financial Results Business Wire

Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag - Business Wire

Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag Business Wire

Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe - Business Wire

Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe Business Wire

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market - Business Wire

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market Business Wire

Dr. Reddy’s Q2 & H1FY25 Financial Results - Business Wire

Dr. Reddy’s Q2 & H1FY25 Financial Results Business Wire

Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America - Business Wire

Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America Business Wire

Dr. Reddy’s Q1FY25 Financial Results - Business Wire

Dr. Reddy’s Q1FY25 Financial Results Business Wire

Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S. - Business Wire

Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S. Business Wire

Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month - Business Wire

Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month Business Wire

Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma’s U.S. Generic Prescription Product Portfolio - Business Wire

Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma’s U.S. Generic Prescription Product Portfolio Business Wire

Dr. Reddy’s Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar - Business Wire

Dr. Reddy’s Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar Business Wire

, a Leading Women’s Health and Dietary Supplements Portfolio of Brands - Business Wire

, a Leading Women’s Health and Dietary Supplements Portfolio of Brands Business Wire

Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries - Business Wire

Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries Business Wire

Dr. Reddy's Laboratories To Acquire Mayne Pharma’s U.S. Generic Prescription Product Portfolio - citybiz

Dr. Reddy's Laboratories To Acquire Mayne Pharma’s U.S. Generic Prescription Product Portfolio citybiz

Dr. Reddy’s Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug - Stock Titan

Dr. Reddy’s Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug Stock Titan

Dr. Reddy's Laboratories Announces the Acquisition of an Injectable Product Portfolio from Eton Pharma - Business Wire

Dr. Reddy's Laboratories Announces the Acquisition of an Injectable Product Portfolio from Eton Pharma Business Wire

Dr. Reddy’s successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe - Business Wire

Dr. Reddy’s successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe Business Wire

Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK - Business Wire

Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK Business Wire

Alvotech and Dr. Reddy’s enter into collaboration for - GlobeNewswire

Alvotech and Dr. Reddy’s enter into collaboration for GlobeNewswire

Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities - Business Wire

Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities Business Wire

Dr. Reddy’s Q4 & FY23 Financial Results - Business Wire

Dr. Reddy’s Q4 & FY23 Financial Results Business Wire

Dr. Reddy's Laboratories Announces the Launch of Lenalidomide Capsules in the U.S. With Two of Six Strengths Eligible for First-to-market, 180-day Exclusivity - Business Wire

Dr. Reddy's Laboratories Announces the Launch of Lenalidomide Capsules in the U.S. With Two of Six Strengths Eligible for First-to-market, 180-day Exclusivity Business Wire

Dr. Reddy's Laboratories Enters Into Definitive Agreement to Acquire German Medical Cannabis Firm Nimbus Health GmbH - Business Wire

Dr. Reddy's Laboratories Enters Into Definitive Agreement to Acquire German Medical Cannabis Firm Nimbus Health GmbH Business Wire

Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S. - PA Media

Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S. PA Media

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. announce the launch of Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. market - Business Wire

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. announce the launch of Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. market Business Wire

Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma - Business Wire

Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma Business Wire

Dr. Reddy’s Recalls Prescription Drug Blister Packages Due to Risk of Poisoning - U.S. Consumer Product Safety Commission (.gov)

Dr. Reddy’s Recalls Prescription Drug Blister Packages Due to Risk of Poisoning U.S. Consumer Product Safety Commission (.gov)

EX-99.1 - SEC.gov

EX-99.1 SEC.gov

Dr. Reddy's Laboratories Announces the Launch of Pyrimethamine Tablets USP, 25 mg, First-Wave Generic Version of Daraprim® in the U.S. Market - Business Wire

Dr. Reddy's Laboratories Announces the Launch of Pyrimethamine Tablets USP, 25 mg, First-Wave Generic Version of Daraprim® in the U.S. Market Business Wire

Akhil Ravi appointed CEO of Aurigene Pharmaceutical Services Ltd. - PharmaLive

Akhil Ravi appointed CEO of Aurigene Pharmaceutical Services Ltd. PharmaLive

Dr. Reddy's Laboratories announces USFDA final approval and launch of Buprenorphine and Naloxone Sublingual Film in the U.S. Market - PR Newswire

Dr. Reddy's Laboratories announces USFDA final approval and launch of Buprenorphine and Naloxone Sublingual Film in the U.S. Market PR Newswire

Generic Version of Vimovo Tablets Now Available - Medical Professionals Reference

Generic Version of Vimovo Tablets Now Available Medical Professionals Reference

Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S. - The Manila Times

Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S. The Manila Times

Dr. Reddy’s Launches Generic Zemplar Injection - Medical Professionals Reference

Dr. Reddy’s Launches Generic Zemplar Injection Medical Professionals Reference

Accutane Generic Zenatane Available Again for Severe Acne - Medical Professionals Reference

Accutane Generic Zenatane Available Again for Severe Acne Medical Professionals Reference

Dr. Reddy's Laboratories announces the launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market - FinancialContent

Dr. Reddy's Laboratories announces the launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market FinancialContent

Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma’s U.S. Generic Prescription Product Portfolio - FinancialContent

Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma’s U.S. Generic Prescription Product Portfolio FinancialContent

Dr. Reddy’s Launches Generic Topical Antifungal Cream - Medical Professionals Reference

Dr. Reddy’s Launches Generic Topical Antifungal Cream Medical Professionals Reference

Dr. Reddy's subsidiary betapharm, and Theranica launch Nerivio® in Germany to provide patients with drug-free migraine treatment - STT Info

Dr. Reddy's subsidiary betapharm, and Theranica launch Nerivio® in Germany to provide patients with drug-free migraine treatment STT Info

Dr. Reddy's Laboratories Announces the Launch of Pemetrexed for Injection USP, in the U.S. Market - FinancialContent

Dr. Reddy's Laboratories Announces the Launch of Pemetrexed for Injection USP, in the U.S. Market FinancialContent

The world’s pill factory | D+C - Development + Cooperation - Dandc.eu

The world’s pill factory | D+C - Development + Cooperation Dandc.eu

Dr. Reddy's subsidiary betapharm, and Theranica launch Nerivio® in Germany to provide patients with drug-free migraine treatment - NTB Kommunikasjon

Dr. Reddy's subsidiary betapharm, and Theranica launch Nerivio® in Germany to provide patients with drug-free migraine treatment NTB Kommunikasjon

Dr. Reddy's subsidiary betapharm, and Theranica launch Nerivio® in Germany to provide patients with drug-free migraine treatment - Via TT

Dr. Reddy's subsidiary betapharm, and Theranica launch Nerivio® in Germany to provide patients with drug-free migraine treatment Via TT

Prestige BioPharma and Dr. Reddy’s announce partnership to commercialize trastuzumab biosimilar in select countries in Latin America and Southeast Asia - ANTARA News

Prestige BioPharma and Dr. Reddy’s announce partnership to commercialize trastuzumab biosimilar in select countries in Latin America and Southeast Asia ANTARA News

This contact info of Dr. Reddy’s regarding 2DG drug procurement is incorrect - FACTLY

This contact info of Dr. Reddy’s regarding 2DG drug procurement is incorrect FACTLY

Dr Reddy's to enhance presence in emerging segments like nutraceuticals, gene therapy - Zee Business

Dr Reddy's to enhance presence in emerging segments like nutraceuticals, gene therapy Zee Business

Dr Reddy's Lab inks licensing pact with US-based Slayback Pharma - Zee Business

Dr Reddy's Lab inks licensing pact with US-based Slayback Pharma Zee Business

Dr. Reddy’s Laboratories announces the launch of Febuxostat Tablets in the U.S. Market - India Education Diary

Dr. Reddy’s Laboratories announces the launch of Febuxostat Tablets in the U.S. Market India Education Diary

Dr Reddy's Labs Q1 results preview: Net profit likely at Rs 1,036 crore, margin may improve by 800 bps - Zee Business

Dr Reddy's Labs Q1 results preview: Net profit likely at Rs 1,036 crore, margin may improve by 800 bps Zee Business

Development and Validation of a Stability Indicating LC Method for the Assay and Related Substances Determination of a Proteasome Inhibitor Bortezomib - Wiley Online Library

Development and Validation of a Stability Indicating LC Method for the Assay and Related Substances Determination of a Proteasome Inhibitor Bortezomib Wiley Online Library

Top Dr. Reddy'S Active Pharmaceutical Ingredients Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant